

Operational experience with RDTs in the private sector



RBM Case Management Working Group Annecy, 5th March 2013



An international research collaboration



Goal: to develop and evaluate mechanisms to improve ACT access, targeting, safety and quality

Cluster Randomised Trials evaluating RDT deployment in:

- Public health facilities: Tanzania, Uganda, Cameroon, Ghana
- Community: Uganda, Afghanistan
- Private sector: Uganda, Nigeria

Descriptive RDT studies in Tanzania, Zanzibar

NMFI studies in northern Tanzania,

Zanzibar & Afghanistan


Safety & drug quality research studies



Ongoing studies



• Can RDTs improve ACT targeting in the private sector?



Tanzania: IMPACT 2




Method and Setting:

Randomly selected private sector outlets in non-urban districts Data collected from clients and attendants

Mwanza (36 outlets)

- No ADDO* registration
- Subsidised ACTs widely available (78% of outlets)
- Parasite Prev: 8.3%



Mtwara (37 outlets)

- ADDO registration & training
- Subsidised ACTs widely available (100% of outlets)
- Parasite Prev: 16.8%


*Accredited Drug Dispensing Outlet

Briggs M *et al.* Prevalence of malaria parasitemia and medication utilization patterns among clients seeking care for malaria or fever in drug shops in Tanzania, March – May 2012. ASTMH 2012. Poster session 24: LB-110.

Tanzania: IMPACT 2 – early results



• Private sector providers rarely base treatment on the results of parasitological tests.



13.5% of Private sector patients with non-severe fever had malaria

~ 69% of those with parasites did NOT buy an ACT

~80% who purchased an ACT did not have malaria

Briggs M *et al.* Prevalence of malaria parasitemia and medication utilization patterns among clients seeking care for malaria or fever in drug shops in Tanzania, March – May 2012. ASTMH 2012. Poster session 24: LB-110.

Tanzania: IMPACT 2 – early results



• Targeting varied between sites

Mwanza No ADDOs Prevalence 8.3% Mtwara ADDOs Prevalence 16.8%

	Purchased ACT	No ACT Purchased		Purchased ACT	No ACT Purchased
Parasitemic	5 (11.9%)	37 (88.1%)	Parasitemic	28 (43.8%)	36 (56.2%)
Not parasitemic	63 (17.4%)	300 (82.6%)	Not parasitemic	67 (21.3%)	248 (78.7%)

• Effect of ADDO (registration and training) unclear: none had RDTs

Briggs M *et al.* Prevalence of malaria parasitemia and medication utilization patterns among clients seeking care for malaria or fever in drug shops in Tanzania, March – May 2012. ASTMH 2012. Poster session A:LB-110.

Uganda: Mbonye et al



- Pragmatic cluster-randomised trial of RDTs in Registered Drug Shops in Mukono district, Uganda.
- Intervention package: low-cost, scalable training and supporting job aids, close supervision for initial 2 months; community sensitisation and signage; free supply of RDT+ Coartem, sold at modest mark-up.
- Evaluation (mixed methods):
 - Targeting of ACTs uptake of testing, impact on subsequent Coartem use
 - Economic outcomes cost effectiveness, willingness to pay
 - Community and provider acceptance, and effect on health system and practice – qualitative research
 - Referral
- Full results: Q1, 2013

Mbonye A *et al.* Introducing rapid diagnostic testing for malaria into the private sector: evidence from an intervention in registered drug shops in Uganda. ASTMH 2012. Poster session A-341.

Uganda: Mbonye et al







A 1100	Total enrolled	Treatment reported by drug shops after end of close support supervision			% ACT	Tx data		
Arm		Coartem	Rectal artesunate	No Coartem	% ACT	missing		
Presumptive	6649	6555	40	14	99%	40		
RDT arm	9366	5312	53	3595	60%	406		
Within RDT arm: 58% unitse								
RDT pos client	5326	5200sit	45	62	99%	19		
RDT neg client	3947	45	7	3523	1%	372		
No RDT result*	93	67	1	10	87%	15		

9% RDT-negatives have unknown treatment status

Adherence to RDT results	RDT Pos	RDT Neg	Overall adherence
Based on treatment reported by DSV	98.8 %	98.5 %	98.7 %
Treating missing data as non-adherence	98.5 %	89.3 %	94.6 %


Mbonye A *et al.* Introducing rapid diagnostic testing for malaria into the private sector: evidence from an intervention in registered drug shops in Uganda. ASTMH 2012. Poster session A-341.

Uganda: Hutchinson *et al*



She [DSV] got to know what she

Community and provider acceptance – Quotes from qualitative research



Hutchinson E et al. "It puts life in us and we feel big": Shifts in the local health-care system during the introduction of RDTm into drug shops in Uganda. ACT Consortium Annual Conference, 2012, unpublished

Uganda: Mbonye et al



Acceptability of RDT testing

- RDT testing at drug shops was viewed as a positive development by both DSVs and patients, generally well accepted
- Few refusals by clients to pay for an RDT (1%), no evidence to suggest that clients stayed away from drug shops using RDTs

Low operator error

- RDTs collected and re-read showed high concordance with readings by DSVs (95%)
- Agreement between RDT readings and light microscopy:
 91% RDT neg were slide negative;
 66% RDT pos were slide positive
- Overdiagnosis by RDTs prolonged positivity due to detection of antigen?

RDT adherence

• Compliance to RDT results by DSVs was high.

Referral by drug shop vendors

- A new concept DSVs referred 25% of RDT-negative patients
- Referral, and follow-up of referral advice, remains a major challenge
- Linkage / integration with the formal health system needs to be strengthened

Ghana: Ansah et al





- Cluster randomised trial in "chemical sellers"
- Package of Interventions: Training, RDTs and demand creation using community engagement – Film and community leaders
- Targeting of ACTs measured data analysis ongoing
- Qualitative research shows RDTs in private sector generally acceptable to community & licensed chemical sellers

• Full results due: Q1, 2013

Ansah E, et al. Preliminary Lessons from the Introduction of mRDTs into the Private retail sector in Ghana. ACT Consortium Annual Conference, 2012 (unpublished)

Nigeria: REACT: Onwujekwe O, et al





- Three arm cluster randomised trial.
- Provider Intervention public clinics, private pharmacies and Patent Medicine Dealers
 - RDT with instructions
 - Training of health workers through workshops
 - Job Aids
 - Supervisory visits
- Community intervention
 - Malaria treatment education in schools
 - Peer-group- education
 - IEC materials
 - Drama production and displays
- Well developed process evaluation
- Results due in Q1/2 2013.



- National programme of subsidized socially marketed RDTs and ACTs in private sector since 2004
 - Piloted in 2001-2002
 - Funded by Global Fund
 - Marketing (Mass media, mobile video unit, job aids)
 - Provider training
 - "Medical detailing"
 - Procurement and supply
- Slow uptake and lack of data since implementation led to the Good Use of ACTs and RDTs (GUARD study):
 - To understand multiple aspects of how RDTs are deployed, performed, used in case management and perceived by providers

Yeung S *et al*: <u>Scaling-up access to malaria diagnosis, country experiences and perspectives.</u> ASTMH 2012. Symposium 14 & ACT Consortium Annual Conference, 2012. Unpublished



- 42 % of providers advised a blood test, of whom 54% offered to perform the test themselves. Mystery client study (n=211)
- Formally trained providers more than untrained (56% of "cabinet" vs 15% of general shops)
- Providers were reluctant to sell antimalarials without prior blood test
- Use of the RDT: Only 38% used correct amount of blood (due to problems with pipette); Only 40% waited for the full 20 minutes; Only 16% disposed of sharps into sharps box
- The most commonly reported diagnosis in RDT negative patients was "typhoid" (67%)

Yeung S *et al*: <u>Scaling-up access to malaria diagnosis, country experiences and perspectives.</u> ASTMH 2012. Symposium 14 & ACT Consortium Annual Conference, 2012. Unpublished




- RDTs can be rolled out in the private sector but
 - Not **all** private sector providers target "diagnosers"?
 - Requires ongoing supportive supervision as well as behaviour change communication
 - Need system for assuring quality
 - Ensure reliable supply of RDTs and ACTs
 - Clarify and support management of "RDT negatives"
 - Some problems with use/blood safety
 - Communication challenge

Willingness to pay: Uganda Hansen *et al*, 2012





• Users of the private sector are willing to pay for RDTs:



70% would pay 700 Sh [0.35 USD] or more 25% would pay 2000 Sh [1.00 USD] or more for an RDT

70% would pay 2000 Sh [1.00 USD] or more 25% would pay 6000 Sh [2.99 USD] or more for a course of ACT

Exit interviews with 519 drug shop clients to inform pricing

Hansen KS *et al.* Willingness-to-pay for a rapid malaria diagnostic test and artemisinin-based combination therapy from private drug shops in Mukono district, Uganda. Health Policy Plan. 2012 May 15.

Observed RDT Prices: Cambodia (Yeung *et al*)



- Cambodia GUARD study (census of 112 private outlets, 2012).
 Subsidised RDTs:
 - Wholesale price 2009 = \$0.50 for box of 10 tests in 2009
 - Median reported buying price (by outlet) was \$0.62 for 10 RDTs (n=112)
 - Recommended Retail Price (not printed) = \$0.24 per test
 - Median price to patient for one test (including doing the test) was US\$0.73 (IQR \$0.49-0.85) with a median absolute mark-up of US\$0.66 per test

Research Needs



• Should RDTs be deployed in the private sector?

Factors to consider in the decision to deploy or not:

- Type of provider
- Cost
- Transmission intensity
- Health system effects
- Access to health services
- Integration of surveillance systems tracking of cases

Importance of a nuanced approach



How can RDT use be optimised?

- What supporting interventions will ensure:
 - Uptake
 - Accuracy
 - Targeting
 - Safety
- What combination of financial and non-financial incentives promote appropriate use of RDTs and ACTs?
- What are the best strategies for management of RDT -ve patients?
- How can private practitioners engage within the health system
 - referral
 - tracking of patients

Summary:



- Need to pay attention to targeting of ACTs in the private sector
- Emerging signs that it is possible to deploy RDTs through some sections of the private sector, with appropriate supportive interventions
 - Improved targeting with compliance to test result Uganda
 - Are acceptable to communities and private providers Uganda, Ghana, Cambodia
 - People are willing to pay for them Uganda, Cambodia
- Ongoing studies will have results in Q1-Q2 2013.

Acknowledgements

Tanzania:

- Catherine Goodman
- Rebecca Thomson
- Patrick Kachur
- Mellissa Briggs

Uganda:

- Sian Clarke
- Anthony Mbonye
- Sham Lal
- Eleanor Hutchinson
- Richard Ndyomugyenyi
- Pascal Magnussen

Ghana [MCDC]:

- Evelyn Ansah
- Chris Whitty



Cambodia:

- Shunmay Yeung
- Chea Nguon
- Mam Boravann
- Ouk Rada
- Patricia Tabernero
- Clare Chandler

Nigeria:

- Obinna Onwujekwe
- Virginia Wiseman
- Lindsay Mangham-Jefferies



ACTc Core Team

- Bonnie Cundill
- Clare Chandler
- Kristian Shultz Hansen
- Shunmay Yeung
- Toby Leslie





